TEL AVIV and BOSTON — January 13, 2026 — Leads & Copy — XTL Biopharmaceuticals Ltd. announced it has entered into a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc.
The acquisition positions XTL as a major player in the autism therapeutics market, addressing a critical unmet medical need. NeuroNOS’s platform targets the core biology of autism, not just symptomatic relief.
NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher from Hebrew University of Jerusalem and Harvard University. The company’s scientific leadership includes two Nobel Laureates in Chemistry: Professor Dan Shechtman (Technion) and Professor Roger Kornberg (Stanford University).
NeuroNOS’s drug development platform is based on small molecules engineered to cross the blood-brain barrier and target diseases associated with nitric oxide (NO) abnormalities in the brain. The company has secured two FDA Orphan Drug Designations for Phelan-McDermid Syndrome (PMS) and Glioblastoma.
XTL will acquire 85% of NeuroNOS for consideration including 19.9% of XTL’s issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million. Milestone payments include clinical development payments of up to $5.5 million to Beyond Air, and commercial milestone payments of up to $26 million upon achieving product sales targets.
NeuroNOS, previously a subsidiary of Beyond Air, will now serve as XTL’s flagship platform for autism and neuro-oncology therapeutics.
Noam Band, Chief Executive Officer of XTL Biopharmaceuticals, said the company is excited to enter the autism field. Steve Lisi, Chairman and CEO of Beyond Air Inc., said the transaction represents a pivotal moment for NeuroNOS.
Autism Spectrum Disorder now affects approximately 1 in 31 children in the United States. There are currently no FDA-approved disease-modifying therapies for autism.
President Donald Trump stated the rise in autism is among the most alarming public health developments in history. Robert F. Kennedy Jr., U.S. Secretary of Health and Human Services, added that autism destroys families and children.
The administration has allocated $50 million in new NIH funding for autism research initiatives.
Preclinical studies have demonstrated that the platform addresses core pathological mechanisms rather than merely alleviating symptoms, validated NO dysregulation has been observed in both autism patients and brain cancer patients.
Corey Davis, Ph.D., LifeSci Advisors, LLC, Cdavis@lifesciadvisors.com, (212) 915-2577
XTL Biopharmaceuticals Ltd., Tel: +972 54 22 88897, Email: info@xtlbio.com
Source: XTL Biopharmaceuticals Ltd.
